3-acetyl-4-hydroxy-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-5-(naphthalen-1-ylmethyl)-1H-pyrrol-2(5H)-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-acetyl-4-hydroxy-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-5-(naphthalen-1-ylmethyl)-1H-pyrrol-2(5H)-one
• 英文别名: 4-acetyl-3-hydroxy-1-[2-(2-methyl-5-nitroimidazol-1-yl)ethyl]-2-(naphthalen-1-ylmethyl)-2H-pyrrol-5-one
• 化学式: C₂₃H₂₂N₄O₅
• 分子量: 434.451
• InChiKey: SIYXJACAJKELIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] TREATMENTS FOR GASTROINTESTINAL CONDITIONS<br/>[FR] TRAITEMENTS DE TROUBLES GASTRO-INTESTINAUX
  申请人：UNIV TEXAS

  公开号：WO2015138753A1

  公开（公告）日：2015-09-17

  Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti-C. difficile compound such as a nitroimidazole and a tetramic acid derivative.

  用于治疗细菌和寄生虫感染的化合物，这些化合物是具有抗细菌或抗寄生虫活性的化合物与减少从胃肠道吸收的混合化合物的混合物。这些化合物主要用于对抗C. difficile感染，并包括一种抗C. difficile化合物（如硝基咪唑）和四环酸衍生物的混合分子。
• Treatments for gastrointestinal conditions
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US10011589B2

  公开（公告）日：2018-07-03

  Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti-C. difficile compound such as a nitroimidazole and a tetramic acid derivative.

  用于治疗细菌和寄生虫感染的化合物，这些化合物是具有抗菌或抗寄生虫活性的化合物与减少胃肠道对混合化合物吸收的化合物的混合化合物。这些化合物优选用于抗艰难梭菌感染，由抗艰难梭菌化合物（如硝基咪唑）和四酸衍生物的混合分子组成。
• TREATMENTS FOR GASTROINTESTINAL CONDITIONS
  申请人：Board of Regents, The University of Texas System

  公开号：EP3116499A1

  公开（公告）日：2017-01-18
• Treatments for Gastrointestinal Conditions
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20170073332A1

  公开（公告）日：2017-03-16

  Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti- C. difficile compound such as a nitroimidazole and a tetramic acid derivative.